ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
Good momentum in commercial CDMO business
The two-part production system is proven to yield high-quality proteins from GS-CHO cell lines, a prevalent mammalian host cell for protein production
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Investment will help fuel international partnerships, grow IGX Platform functionality, and diversify proposition with new generative AI solutions
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield
Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Subscribe To Our Newsletter & Stay Updated
